205 related articles for article (PubMed ID: 28145100)
1. Profiling of microRNAs in tumor interstitial fluid of breast tumors - a novel resource to identify biomarkers for prognostic classification and detection of cancer.
Halvorsen AR; Helland Å; Gromov P; Wielenga VT; Talman MM; Brunner N; Sandhu V; Børresen-Dale AL; Gromova I; Haakensen VD
Mol Oncol; 2017 Feb; 11(2):220-234. PubMed ID: 28145100
[TBL] [Abstract][Full Text] [Related]
2. N-glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome.
Terkelsen T; Haakensen VD; Saldova R; Gromov P; Hansen MK; Stöckmann H; Lingjaerde OC; Børresen-Dale AL; Papaleo E; Helland Å; Rudd PM; Gromova I
Mol Oncol; 2018 Jun; 12(6):972-990. PubMed ID: 29698574
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Tumor Secretome from Tumor Interstitial Fluid (TIF).
Gromov P; Gromova I
Methods Mol Biol; 2016; 1459():231-47. PubMed ID: 27665563
[TBL] [Abstract][Full Text] [Related]
4. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.
Schaaij-Visser TB; de Wit M; Lam SW; Jiménez CR
Biochim Biophys Acta; 2013 Nov; 1834(11):2242-58. PubMed ID: 23376433
[TBL] [Abstract][Full Text] [Related]
5. Tumor interstitial fluid - a treasure trove of cancer biomarkers.
Gromov P; Gromova I; Olsen CJ; Timmermans-Wielenga V; Talman ML; Serizawa RR; Moreira JM
Biochim Biophys Acta; 2013 Nov; 1834(11):2259-70. PubMed ID: 23416532
[TBL] [Abstract][Full Text] [Related]
6. Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.
Gromov P; Gromova I; Bunkenborg J; Cabezon T; Moreira JM; Timmermans-Wielenga V; Roepstorff P; Rank F; Celis JE
Mol Oncol; 2010 Feb; 4(1):65-89. PubMed ID: 20005186
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential.
Wang W; Luo YP
J Zhejiang Univ Sci B; 2015 Jan; 16(1):18-31. PubMed ID: 25559952
[TBL] [Abstract][Full Text] [Related]
8. High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.
Terkelsen T; Pernemalm M; Gromov P; Børresen-Dale AL; Krogh A; Haakensen VD; Lethiö J; Papaleo E; Gromova I
Mol Oncol; 2021 Feb; 15(2):429-461. PubMed ID: 33176066
[TBL] [Abstract][Full Text] [Related]
9. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
10. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.
Celis JE; Gromov P; Cabezón T; Moreira JM; Ambartsumian N; Sandelin K; Rank F; Gromova I
Mol Cell Proteomics; 2004 Apr; 3(4):327-44. PubMed ID: 14754989
[TBL] [Abstract][Full Text] [Related]
11. Identification of protein clusters predictive of response to chemotherapy in breast cancer patients.
Cortesi L; Barchetti A; De Matteis E; Rossi E; Della Casa L; Marcheselli L; Tazzioli G; Lazzaretti MG; Ficarra G; Federico M; Iannone A
J Proteome Res; 2009 Nov; 8(11):4916-33. PubMed ID: 19739612
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs as potential biomarkers in cancer: opportunities and challenges.
Lan H; Lu H; Wang X; Jin H
Biomed Res Int; 2015; 2015():125094. PubMed ID: 25874201
[TBL] [Abstract][Full Text] [Related]
13. Interstitial Fluid in Gynecologic Tumors and Its Possible Application in the Clinical Practice.
Ura B; Di Lorenzo G; Romano F; Monasta L; Mirenda G; Scrimin F; Ricci G
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30545144
[TBL] [Abstract][Full Text] [Related]
14. [MicroRNAs as potential noninvasive markers in the diagnosis of urological malignancies].
Gilyazova IR; Klimentova EA; Pavlov VN; Khusnutdinova EK
Urologiia; 2016 Apr; (2):96-102. PubMed ID: 28247670
[TBL] [Abstract][Full Text] [Related]
15. Plasma exosome microRNAs are indicative of breast cancer.
Hannafon BN; Trigoso YD; Calloway CL; Zhao YD; Lum DH; Welm AL; Zhao ZJ; Blick KE; Dooley WC; Ding WQ
Breast Cancer Res; 2016 Sep; 18(1):90. PubMed ID: 27608715
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers Found in the Tumor Interstitial Fluid may Help Explain the Differential Behavior Among Keratinocyte Carcinomas.
Matas-Nadal C; Bech-Serra JJ; Gatius S; Gomez X; Ribes-Santolaria M; Guasch-Vallés M; Pedraza N; Casanova JM; de la Torre Gómez C; Garí E; Aguayo-Ortiz RS
Mol Cell Proteomics; 2023 Jun; 22(6):100547. PubMed ID: 37059366
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
18. Quantitative measurement of serum microRNA-21 expression in relation to breast cancer metastasis in Chinese females.
Wang G; Wang L; Sun S; Wu J; Wang Q
Ann Lab Med; 2015 Mar; 35(2):226-32. PubMed ID: 25729725
[TBL] [Abstract][Full Text] [Related]
19. Tumor interstitial fluid: proteomic determination as a possible source of biomarkers.
Baronzio G; Parmar G; Baronzio M; Kiselevsky M
Cancer Genomics Proteomics; 2014; 11(5):225-37. PubMed ID: 25331795
[TBL] [Abstract][Full Text] [Related]
20. MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy.
Zhong X; Xie G; Zhang Z; Wang Z; Wang Y; Wang Y; Qiu Y; Li L; Bu H; Li J; Zheng H
Oncotarget; 2016 Sep; 7(38):61166-61182. PubMed ID: 27533459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
